Yahoo
TSXV - Delayed Quote CAD

NurExone Biologic Inc. (NRX.V)

0.5000 -0.0100 (-1.96%)
At close: November 3 at 11:35:03 AM EST
Chart Range Bar
Loading chart for NRX.V
  • Previous Close 0.5100
  • Open 0.4900
  • Bid 0.4900 x --
  • Ask 0.5100 x --
  • Day's Range 0.4900 - 0.5000
  • 52 Week Range 0.4350 - 0.7600
  • Volume 2,500
  • Avg. Volume 22,769
  • Market Cap (intraday) 46.023M
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1100
  • Earnings Date (est.) Nov 25, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.

nurexone.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

NRX.V
26.47%
S&P/TSX Composite index (^GSPTSE)
11.50%

1-Year Return

NRX.V
28.57%
S&P/TSX Composite index (^GSPTSE)
17.42%

3-Year Return

NRX.V
66.67%
S&P/TSX Composite index (^GSPTSE)
79.23%

5-Year Return

NRX.V
16.28%
S&P/TSX Composite index (^GSPTSE)
67.09%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings --
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -142.12%

  • Return on Equity (ttm)

    -450.96%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -6.31M

  • Diluted EPS (ttm)

    -0.1100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.01M

  • Total Debt/Equity (mrq)

    4.11%

  • Levered Free Cash Flow (ttm)

    -1.6M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: